Euro Q4 Consumer Health Earnings Preview: Sanofi, Bayer, Reckitt And Haleon

 
• By Tom Gallen
  
Generate a summary of this article
Listen to this article
Beta

Major Europe-based consumer health players Sanofi Bayer, Reckitt and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q4 2022 results over the coming weeks.

• Source: Alamy

Sanofi will report its Q4 results from its Paris headquarters on 3 February with a long running national paracetamol shortage continuing to rumble on in the background. The issue, which began during the summer, mainly concerns pediatric paracetamol forms, such as oral suspensions and suppositories. Sanofi is the leading supplier of paracetamol in France, with children’s and adult presentations marketed under its Doliprane brand.

Measures introduced by French drug regulator ANSM back in July – including placing limits on orders of paracetamol by pharmacists...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Europe

EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs

In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By David Ridley

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Marinomed Starts Restructuring Proceedings As Debts Mount

 
• By Tom Gallen

Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.

Perrigo Adds High-Strength Paracetamol To UK Solpadeine Line

 
• By David Ridley

Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative. 

More from Geography

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 
• By Malcolm Spicer

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By David Ridley

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.